Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency

FDA recall notice · announced August 21, 2026 · Vitruvias Therapeutics

Class I FDA/FSIS Class I: reasonable probability that use will cause serious adverse health consequences or death.

The product

Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.

Reason for recall

Superpotent Drug

Notes

Distribution: US Nationwide.
Lot/code information: Lot # 504950, Exp Date: 09/30/2026.
Quantity: 1955 bottles
Status: Ongoing
Products in this recall event:
- Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Pro (D-0866-2026)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.